Correlations between Demographic, Clinical, and Paraclinical Variables and Outcomes in Patients with KRAS-Mutant or KRAS Wild-Type Metastatic Colorectal Cancer—A Retrospective Study from a Tertiary-Level Center in Romania

Author:

Pîrvu Edvina Elena12,Severin Emilia1,Pătru Raluca Ileana2,Niță Irina3,Toma Stefania Andreea4,Macarie Roxana Rodica2,Cocioabă Cristina Elena2,Florescu Ioana2,Coniac Simona2

Affiliation:

1. Department of Genetics, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania

2. Department of Medical Oncology, “Coltea” Clinical Hospital, 030167 Bucharest, Romania

3. Department of Medical Oncology, Medicover Hospital, 020331 Bucharest, Romania

4. Department of Medical Oncology, Ponderas Academic Hospital, 014142 Bucharest, Romania

Abstract

Colorectal cancer (CRC) is a significant global public health concern and its characteristics in Eastern Europe are underexplored. In this retrospective study, data of 225 patients with metastatic colorectal cancer (mCRC) from the Colțea Clinical Hospital’s Oncology Department in Bucharest were analyzed between 2015 and 2023. They were divided into two groups based on the presence of KRAS mutation. The primary objective of the study was to investigate whether the presence of KRAS mutations influenced the prognosis of mCRC and to identify any demographic, clinical, or paraclinical factors associated with KRAS mutations in stage IV CRC. The overall survival for the entire study population was 29 months. There was a trend towards increased survival in the KRAS wild-type group (31 months) compared to the KRAS-mutant group (26 months), but this difference did not reach statistical significance. We found that lower levels of education, advanced T stage, advanced N stage, and M1 stage at diagnosis negatively impacted prognosis. Real-world data are crucial in shaping public policy strategies to better support patients with metastatic CRC. Understanding the correlations between the demographic, clinical, and paraclinical variables and the outcomes in mCRC patients with KRAS-mutant and KRAS wild-type colorectal cancer is essential for improving patient care and treatment strategies in Romania and beyond.

Publisher

MDPI AG

Subject

Clinical Biochemistry

Reference43 articles.

1. The International Agency for Research on Cancer (IARC) (2023, April 10). Global Cancer Observatory. Available online: https://gco.iarc.fr/.

2. Global Burden of Colorectal Cancer in 2020 and 2040: Incidence and Mortality Estimates from GLOBOCAN;Eileen;Gut,2023

3. Metastatic Colorectal Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up;Cervantes;Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.,2023

4. Precision Therapy in RAS Mutant Colorectal Cancer;Dienstmann;Gastroenterology,2020

5. Therneau, T.M., Lumley, T., Elizabeth, A., and Cynthia, C. (2023, March 12). Survival: Survival Analysis. Available online: https://cran.r-project.org/web/packages/survival/index.html.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3